Bank of America Raises Hims & Hers Health (NYSE:HIMS) Price Target to $25.00

Hims & Hers Health (NYSE:HIMS) had its price objective increased by Bank of America from $23.00 to $25.00 in a research report report published on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

HIMS has been the subject of several other reports. Jefferies Financial Group raised their target price on shares of Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, June 27th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research note on Wednesday, August 7th. Truist Financial boosted their target price on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, July 18th. Piper Sandler reiterated a “neutral” rating and issued a $18.00 target price on shares of Hims & Hers Health in a report on Tuesday, August 6th. Finally, Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Eight analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, Hims & Hers Health presently has a consensus rating of “Moderate Buy” and an average price target of $20.21.

Hims & Hers Health Price Performance

Shares of HIMS stock opened at $21.38 on Monday. Hims & Hers Health has a 1-year low of $5.65 and a 1-year high of $25.74. The business’s fifty day moving average price is $17.24 and its 200 day moving average price is $17.73. The firm has a market capitalization of $4.59 billion, a PE ratio of 272.91 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The business had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. During the same quarter last year, the firm posted ($0.03) EPS. The business’s revenue was up 51.8% compared to the same quarter last year. Equities research analysts expect that Hims & Hers Health will post 0.22 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $16.47, for a total transaction of $3,110,985.36. Following the sale, the chief executive officer now directly owns 33,502 shares in the company, valued at $551,777.94. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, insider Michael Chi sold 7,500 shares of the company’s stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $22.20, for a total value of $166,500.00. Following the completion of the transaction, the insider now owns 193,980 shares of the company’s stock, valued at $4,306,356. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $16.47, for a total transaction of $3,110,985.36. Following the sale, the chief executive officer now owns 33,502 shares in the company, valued at approximately $551,777.94. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 841,076 shares of company stock valued at $14,759,219 over the last 90 days. 17.71% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently made changes to their positions in HIMS. Vanguard Group Inc. raised its holdings in Hims & Hers Health by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 14,173,285 shares of the company’s stock worth $126,142,000 after purchasing an additional 46,541 shares during the last quarter. B. Riley Wealth Advisors Inc. acquired a new position in Hims & Hers Health in the fourth quarter valued at $155,000. Los Angeles Capital Management LLC boosted its position in Hims & Hers Health by 58.5% during the first quarter. Los Angeles Capital Management LLC now owns 28,206 shares of the company’s stock valued at $436,000 after acquiring an additional 10,405 shares during the last quarter. Counterpoint Mutual Funds LLC bought a new stake in Hims & Hers Health during the first quarter valued at $285,000. Finally, State of Michigan Retirement System acquired a new stake in Hims & Hers Health during the 1st quarter worth about $2,785,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.